Instead, it reveals predispositions in peptide and metabolic pathways that may help explain why some patients experience more pronounced fatigue than others
Rausch C, Borthakur G, Haddad F, Chien K, Hammond D, Montalban-Bravo G, Pemmaraju N, Masarova L, Yilmaz M, Andreeff M , Jabbour E, Burger J, Jain N, Ravandi F, Kadia T
Now, two new late-phase clinical trials, sponsored by Eli Lilly and Company, suggest that transitioning from high dose injectable weight loss medications to either a daily pill or a lower maintenance dose can help people living with obesity to keep off most of the weight they have already lost The results of the ATTAIN-MAINTAIN and SURMOUNT-MAINTAIN trials were presented at the European Congress on Obesity and published in Previous research suggests that 1 year after stopping weight loss medication, people may regain, on average, 60% of their lost weight
doi: 10.1007/s00432-003-0510-2 22 MemonRATecottLHNonogakiKBeigneuxAMoserAHGrunfeldCet al
The reasons are biological, not cosmetic
Understanding the actual clinical evidence can help you make an informed decision about tirzepatide therapy with PlexusDx
